← FDA DRUG APPROVALS

FDA ANDA · ANDA204693

EPTIFIBATIDE

Sponsor: SAGENT PHARMS INC

APPLICATION
ANDA204693
TYPE
ANDA
ORIGINAL APPROVAL
2018-03-07
LATEST ACTION
2025-03-25
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

EPTIFIBATIDEPrescription
EPTIFIBATIDE 2MG/ML · INJECTABLE · INJECTION
EPTIFIBATIDEPrescription
EPTIFIBATIDE 75MG/100ML · INJECTABLE · INJECTION

Approval history

2025-03-25Labeling · Supplement 1 · standardAP
2018-03-07UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →